5% Imiquimod Cream for the Treatment of Large Superficial Basal Cell Carcinoma

Shumack, Stephen; Gebauer, Kurt; Quirk, Christopher J; Macdonald, Ken; Walters, Shelley-Ann; Owens, Mary

doi:10.1001/archderm.140.10.1286

Cited by 21 publications

(24 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Micronodular BCC is one of the more invasive forms of BCC with a higher tendency to recur 10 if inadequately excised than standard nodular BCC and MMS is indicated for this histologic subtype. The decreasing trend of superficial BCC treated with MMS could be explained by the introduction of two new treatments with less potential for scarring over the past 10 years: topical imiquimod 11,12 and photodynamic therapy. 13,14 Recent publications have demonstrated the efficacy of these treatments in short-term clearance of superficial BCC [12][13][14] ; long-term recurrences have not yet been assessed.…”

Section: Resultsmentioning

confidence: 99%

Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007)

Lim¹,

Paver²,

Peñas³

2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007)

Lim¹,

Paver²,

Peñas³

2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Clearance rates of imiquimod for the treatment of superficial BCC are shown in Table . 5FU 5% cream has been studied in the treatment of superficial BCC; results are shown in Table .…”

Section: Methodsmentioning

confidence: 99%

Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons

Chitwood

Etzkorn

Cohen

2013

Dermatologic Surgery

View full text Add to dashboard Cite

show abstract

“…Finally, some case reports (no RCTs) have claimed positive responses to topical IQ 5% in large superfi cial BCCs (Shumack et al 2004;Micali et al 2005) and multiple BCCs as observed in Gorlin syndrome (Kagy and Amonette 2000;Micali, Lacarrubba, et al 2003).…”

Section: Basal Cell Carcinomamentioning

confidence: 99%

Advances in the use of topical imiquimod to treat dermatologic disorders

Micali¹

2008

TCRM

View full text Add to dashboard Cite

Imiquimod (IQ) is an immune-response modifying agent, fi rst approved by FDA for the topical treatment of external genital and perianal warts in 1997. It induces, through stimulation of Toll-like receptors (TLRs) localized on the surface of antigen-presenting cells, synthesis and release of several endogenous pro-infl ammatory cytokines such as interferon-α (IFN-α), tumor necrosis factor-α (TNF-α) and interleukins (IL) 6 and 12, which in turn stimulate both the innate and acquired immune pathways, resulting in upregulation of natural antiviral and antitumor activity. IQ 5% cream has been used for the treatment of a wide variety of dermatologic conditions in which the immune system is thought to play a role in regression of the disease. In some disorders, such as genital and perianal warts, actinic keratoses, basal cell carcinomas, Bowen's disease and molluscum contagiosum, relative safety and effi cacy are supported by randomized controlled trials of IQ. However, it is common for patients to experience local skin reactions, which can range from mild to severe in intensity, but usually resolve 1-2 weeks after interrupting treatment. Additional randomized trials are encouraged to assess safety and effi cacy of IQ in the treatment of an even wider range of cutaneous disorders.

show abstract

5% Imiquimod Cream for the Treatment of Large Superficial Basal Cell Carcinoma

Cited by 21 publications

References 2 publications

Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007)

Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007)

Topical and Intralesional Treatment of Nonmelanoma Skin Cancer: Efficacy and Cost Comparisons

Advances in the use of topical imiquimod to treat dermatologic disorders

Contact Info

Product

Resources

About